| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Coleman Mark serves as a Director at AXSM. Across recent SEC filings that breaks down to 11 buys and 12 sells. Those positions are worth an estimated $7.6M at current prices.
Historically, Coleman Mark's trades have earned a below-average insider score of 37/100 across 9 rated trades. Over a 12-month horizon, 12.5% of those trades were profitable, with an average 12-month return of -49.4%.
The biggest single holding is AXSM (~$7.6M) as Director. The recent filings there lean toward selling, a net 63,660 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2020 | AXSM Axsome Therapeutics, Inc. | Director | Buy | 650 | $78.50 | $51,025.00 | +0.2% | |
| Jun 26, 2019 | AXSM Axsome Therapeutics, Inc. | Director | Buy | 16,200 | $23.10 | $374,280.00 | +2.5% | |
| May 13, 2019 | AXSM Axsome Therapeutics, Inc. | Director | Buy | 4,650 | $21.44 | $99,696.00 | +0.7% | |
| Mar 19, 2019 | AXSM Axsome Therapeutics, Inc. | Director | Buy | 5,100 | $12.18 | $62,118.00 | New |